Skip Navigation


JAC Advance Access originally published online on June 10, 2008
Journal of Antimicrobial Chemotherapy 2008 62(3):434-436; doi:10.1093/jac/dkn229
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/3/434    most recent
dkn229v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zhao, X.
Right arrow Articles by Drlica, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, X.
Right arrow Articles by Drlica, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Leading articles

A unified anti-mutant dosing strategy

Xilin Zhao and Karl Drlica*

Public Health Research Institute, New Jersey Medical School, UMDNJ, 225 Warren Street, Newark, NJ 07103, USA

* Corresponding author. Tel: +1-973-854-3360; Fax: +1-973-854-3101; E-mail: drlicaka{at}umdnj.edu

Antimicrobial dosing is currently attracting attention as a way to minimize the emergence of resistance. Three dose-based strategies have been advocated, each with shortcomings. Focus on killing susceptible cells overlooks resistant mutant subpopulations that may be present before treatment or generated during therapy; keeping therapeutic drug concentrations above the mutant prevention concentration (MPC; resistant mutant MIC) may be overly stringent; and dosage escalation modelling uses indirect estimates of resistant mutant subpopulation susceptibility (multiples of bulk population susceptibility, MIC) rather than direct estimates from MPC. The latter is significant because MPC and MIC are discordant with multiple pathogen isolates. Combining the strategies leads to MPC-based PK/PD thresholds (e.g. AUC24/MPC and t > MPC) for restricting resistant subpopulation enrichment and amplification. Using MPC-based thresholds to model dosing regimens that will restrict emergence of resistance requires generation of databases in which MPC is determined for many isolates.

Keywords: MPC , PK/PD indices , mutant selection window


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A.-S. Kesteman, A. A. Ferran, A. Perrin-Guyomard, M. Laurentie, P. Sanders, P.-L. Toutain, and A. Bousquet-Melou
Influence of Inoculum Size and Marbofloxacin Plasma Exposure on the Amplification of Resistant Subpopulations of Klebsiella pneumoniae in a Rat Lung Infection Model
Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4740 - 4748.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. P. Allen and C. D. Hankins
Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae
J. Antimicrob. Chemother., August 1, 2009; 64(2): 359 - 363.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.